Background: Matrix metalloproteinases 1 (MMP1) plays a role in cancer development and metastasis and high expression of MMP1 has been confirmed in various types of cancers. However, the correlation between MMP1 and prognosis and tumor-infiltration lymphocytes in breast cancer remains uncertain. In this present study, we analyzed MMP1 expression and correlation with prognosis of cancer patients in databases such as Oncomine, PrognoScan, and Kaplan-Meier plotter. In addition, we investigated the correlation of MMP1 with tumor-infiltrating immune cells in the different tumor microenvironments via Tumor Immune Estimation Resource (TIMER). Methods: MMP1 expression was analyzed via the Oncomine database and Tumor Immune Estimation Resource (TIMER) site. The prognosis of MMP1 on cancers was analyzed using Kaplan-Meier plotter, the PrognoScan database and Gene Expression Profiling Interactive Analysis (GEPIA). The correlations between MMP1 and cancer immune infiltration were investigated by TIMER. In addition, correlations betweenMMP1 expression and gene marker sets of immune infiltration were analyzed by TIMER and GEPIA. Results: MMP1 is highly expressed in most cancers and correlated to poor prognosis. MMP1 expression is significantly linked with a poorer prognosis in breast cancer (OS HR 1.78, 95% CI = 1.59 - 1.98, P < 0.0001; RFS HR 1.82, 95% CI = 1.19 - 2.80, P = 0.0053) and breast cancer (OS HR 2.63, P = 0.02). In addition, the expression of MMP1 was significantly associated with levels of CD8 + T cell (R = 0.464, P = 2.97e-54), CD8 + T cell (R = − 0.134, P = 2.17e-05), macrophage (R = 0.41, P = 1.11e-08), dendritic cell (R = 0.221, P = 2.92e-03) and NK cell (R = 0.213, P = 4.15e-03). Besides, MMP1 expression is significantly associated with the marker genes of immune cells (P < 0.001). Conclusions: Our study indicates that MMP1 is correlated with prognosis and immune infiltrating levels of CD8 + T cell, CD8 + T cell, macrophage, dendritic cell and NK cells in breast cancer. Besides, MMP1 expression potentially contributes to regulation of T cell, B cell, tumor-associated macrophages (TAMs), DCs, T cell exhaustion and Tregs in colon and gastric cancer. The results indicate that MMP1 can be used as a prognostic biomarker for determining prognosis and immune infiltration in breast cancer.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
Alsop, B.R. and Sharma, P. (2016) Esophageal Cancer. Gastroenterology Clinics of North America, 45, 399-412. https://doi.org/10.1016/j.gtc.2016.04.001
Kato, H. and Nakajima, M. (2013) Treatments for Esophageal Cancer: A Review. General Thoracic and Cardiovascular Surgery, 61, 330-335. https://doi.org/10.1007/s11748-013-0246-0
Bollschweiler, E., Plum, P., Monig, S.P., et al. (2017) Current and Future Treatment Options for Esophageal Cancer in the Elderly. Expert Opinion on Pharmacotherapy, 18, 1001-1010. https://doi.org/10.1080/14656566.2017.1334764
Waks, A.G. and Winer, E.P. (2019) Breast Cancer Treatment: A Review. JAMA, 321, 288-300. https://doi.org/10.1001/jama.2018.19323
Furrukh, M. and Qureshi, A. (2018) Treatment of Breast Cancer: Review and Updates. Journal of Ayub Medical College Abbottabad, 30, 264-274.
Harbeck, N. and Gnant, M. (2017) Breast Cancer. The Lancet, 389, 1134-1150. https://doi.org/10.1016/S0140-6736(16)31891-8
Thorat, M.A. and Balasubramanian, R. (2020) Breast Cancer Prevention in High-Risk Women. Best Practice & Research Clinical Obstetrics & Gynaecology, 65, 18-31. https://doi.org/10.1016/j.bpobgyn.2019.11.006
Zhou, Z., Ma, X., Wang, F., Sun, L. and Zhang, G. (2018) A Matrix Metalloproteinase-1 Polymorphism, MMP1-1607 (1G>2G), Is Associated with Increased Cancer Risk: A Meta-Analysis Including 21,327 Patients. Disease Markers, 2018, Article ID: 7565834. https://doi.org/10.1155/2018/7565834
Decock, J., Thirkettle, S., Wagstaff, L. and Edwards, D.R. (2011) Matrix Metalloproteinases: Protective Roles in Cancer. Journal of Cellular and Molecular Medicine, 15, 1254-1265. https://doi.org/10.1111/j.1582-4934.2011.01302.x
Cui, N., Hu, M., and Khalil, R.A. (2017) Biochemical and Biological Attributes of Matrix Metalloproteinases. Progress in Molecular Biology and Translational Science, 147, 1-73. https://doi.org/10.1016/bs.pmbts.2017.02.005
Murray, G.I., Duncan, M.E., O’Neil, P., McKay, J.A., Melvin, W.T. and Fothergill, J.E. (1998) Matrix Metalloproteinase-1 Is Associated with Poor Prognosis in Oesophageal Cancer. The Journal of Pathology, 185, 256-261. https://doi.org/10.1002/(SICI)1096-9896(199807)185:3%3C256::AID-PATH115%3E3.0.CO;2-A
Altadill, A., Rodríguez, M., González, L.O., Junquera, S., Corte, M.D., González-Dieguez, M.L., et al. (2009) Liver Expression of Matrix Metalloproteases and Their Inhibitors in Hepatocellular Carcinoma. Digestive and Liver Disease, 41, 740-748. https://doi.org/10.1016/j.dld.2009.01.016
Inoue, T., Yashiro, M., Nishimura, S., Maeda, K., Sawada, T., Ogawa, Y., et al. (1999) Matrix Metalloproteinase-1 Expression Is a Prognostic Factor for Patients with Advanced Gastric Cancer. International Journal of Molecular Medicine, 4, 73-80. https://doi.org/10.3892/ijmm.4.1.73
Du, X., Wang, S., Lu, J., Cao, Y., Song, N., Yang, T., et al. (2011) Correlation between MMP1-PAR1 Axis and Clinical Outcome of Primary Gallbladder Carcinoma. Japanese Journal of Clinical Oncology, 41, 1086-1093. https://doi.org/10.1093/jjco/hyr108
Mizrachi, A., Koren, R., Hadar, T., Yaniv, E., Morgenstern, S. and Shvero, J. (2011) Expression of MMP-1 in Invasive Well-Differentiated Thyroid Carcinoma. European Archives of Oto-Rhino-Laryngology, 268, 131-135. https://doi.org/10.1007/s00405-010-1343-7
Ozden, F., Saygin, C., Uzunaslan, D., Onal, B., Durak, H. and Aki, H. (2013) Expression of MMP-1, MMP-9 and TIMP-2 in Prostate Carcinoma and Their Influence on Prognosis and Survival. Journal of Cancer Research and Clinical Oncology 139, 1373-1382. https://doi.org/10.1007/s00432-013-1453-x
Murray, G.I., Duncan, M.E., O’Neil, P., Melvin, W.T. and Fothergill, J.E. (1996) Matrix Metalloproteinase-1 Is Associated with Poor Prognosis in Colorectal Cancer. Nature Medicine, 2, 461-462. https://doi.org/10.1038/nm0496-461
Rhodes, D.R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., et al. (2004) ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform. Neoplasia, 6, 1-6. https://doi.org/10.1016/S1476-5586(04)80047-2
Rhodes, D.R., Kalyana-Sundaram, S., Mahavisno, V., Varambally, R., Yu, J., Briggs, B.B., et al. (2007) Oncomine 3.0: Genes, Pathways, and Networks in a Collection of 18,000 Cancer Gene Expression Profiles. Neoplasia, 9, 166-180. https://doi.org/10.1593/neo.07112
Mizuno, H., Kitada, K., Nakai, K. and Sarai, A. (2009) PrognoScan: A New Database for Meta-Analysis of the Prognostic Value of Genes. BMC Medical Genomics, 2, Article No. 18. https://doi.org/10.1186/1755-8794-2-18
Yuan, Q., Sun, N., Zheng, J., Wang, Y., Yan, X., Mai, W., Liao, Y. and Chen, X. (2020) Prognostic and Immunological Role of FUN14 Domain Containing 1 in Pan-Cancer: Friend or Foe? Frontiers in Oncology, 10, Article No. 1502. https://doi.org/10.3389/fonc.2019.01502
Gyorffy, B., Lanczky, A., Eklund, A.C., Denkert, C., Budczies, J., Li, Q., et al. (2010) An Online Survival Analysis Tool to Rapidly Assess the Effect of 22,277 Genes on Breast Cancer Prognosis Using Microarray Data of 1,809 Patients. Breast Cancer Research and Treatment, 123, 725-731. https://doi.org/10.1007/s10549-009-0674-9
Gyorffy, B., Surowiak, P., Budczies, J. and Lánczky, A. (2013) Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer. PLoS ONE, 8, Article ID: e82241. https://doi.org/10.1371/journal.pone.0082241
Gyorffy, B., Lánczky, A. and Szállási Z. (2012) Implementing an Online Tool for Genome-Wide Validation of Survival-Associated Biomarkers in Ovarian-Cancer Using Microarray Data from 1287 Patients. International Journal of Molecular Medicine, 19, 197-208. https://doi.org/10.1530/ERC-11-0329
Szász, A.M., Lánczky, A., Nagy, á., Forster, S., Hark, K., Green, J.E., et al. (2016) Cross-Validation of Survival Associated Biomarkers in Gastric Cancer Using Transcriptomic Data of 1,065 Patients. Oncotarget, 7, 49322-49333. https://doi.org/10.18632/oncotarget.10337
Li, T., Fu, J., Zeng, Z., Cohen, D., Li, J., Chen, Q., et al. (2020) TIMER2.0 for Analysis of Tumor-Infiltrating Immune Cells. Nucleic Acids Research, 48, W509-W514. https://doi.org/10.1093/nar/gkaa407
Tang, Z., Li, C., Kang, B., Gao, G., Li, C. and Zhang, Z. (2017) GEPIA: A Web Server for Cancer and Normal Gene Expression Profiling and Interactive Analyses. Nucleic Acids Research, 45, W98-W102. https://doi.org/10.1093/nar/gkx247
Tsang, J.Y.S. and Tse, G.M. (2020) Molecular Classification of Breast Cancer. Advances in Anatomic Pathology, 27, 27-35. https://doi.org/10.1097/PAP.0000000000000232
Mook, S., Schmidt, M.K., Rutgers, E.J., van de Velde, A.O., Visser, O., Rutgers, S.M., et al. (2009) Calibration and Discriminatory Accuracy of Prognosis Calculation for Breast Cancer with the Online Adjuvant! Program: A Hospital-Based Retrospective Cohort Study. The Lancet Oncology, 10, 1070-1076. https://doi.org/10.1016/S1470-2045(09)70254-2
Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B.I., Weber, K.E., et al. (2018) Tumour-Infiltrating Lymphocytes and Prognosis in Different Subtypes of Breast Cancer: A Pooled Analysis of 3771 Patients Treated with Neoadjuvant Therapy. The Lancet Oncology, 19, 40-50. https://doi.org/10.1016/S1470-2045(17)30904-X
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B.M., Komor, M., et al. (2010) Tumor-Associated Lymphocytes as an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer. Journal of Clinical Oncology, 28, 105-113. https://doi.org/10.1200/JCO.2009.23.7370
Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P.K., Smyth, M.J., et al. (2016) Clinical Relevance of Host Immunity in Breast Cancer: From TILs to the Clinic. Nature Reviews Clinical Oncology, 13, 228-241. https://doi.org/10.1038/nrclinonc.2015.215
McGranahan, N. and Swanton, C. (2017) Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell, 168, 613-628. https://doi.org/10.1016/j.cell.2017.01.018